HARS2
Histidine--tRNA ligase, mitochondrial
Also known as: HARSL, HARSR, HO3, SYHM_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P49590
- Gene
- HARS2
- Ensembl
- ENSG00000112855
- Chromosome
- 5
- Canonical length
- 506 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Mitochondria
- Quaternary structure
- Homodimer
OverviewNCBI Gene
Aminoacyl-tRNA synthetases are a class of enzymes that charge tRNAs with their cognate amino acids. The protein encoded by this gene is an enzyme belonging to the class II family of aminoacyl-tRNA synthetases. Functioning in the synthesis of histidyl-transfer RNA, the enzyme plays an accessory role in the regulation of protein biosynthesis. The gene is located in a head-to-head orientation with HARS on chromosome five, where the homologous genes likely share a bidirectional promoter. Mutations in this gene are associated with the pathogenesis of Perrault syndrome, which involves ovarian dysgenesis and sensorineural hearing loss. Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jul 2013]
Canonical amino-acid sequenceUniProt
506 residues, UniProt reviewed canonical sequence.
>P49590|HARS2
1 MPLLGLLPRR AWASLLSQLL RPPCASCTGA VRCQSQVAEA VLTSQLKAHQ EKPNFIIKTP
61 KGTRDLSPQH MVVREKILDL VISCFKRHGA KGMDTPAFEL KETLTEKYGE DSGLMYDLKD
121 QGGELLSLRY DLTVPFARYL AMNKVKKMKR YHVGKVWRRE SPTIVQGRYR EFCQCDFDIA
181 GQFDPMIPDA ECLKIMCEIL SGLQLGDFLI KVNDRRIVDG MFAVCGVPES KFRAICSSID
241 KLDKMAWKDV RHEMVVKKGL APEVADRIGD YVQCHGGVSL VEQMFQDPRL SQNKQALEGL
301 GDLKLLFEYL TLFGIADKIS FDLSLARGLD YYTGVIYEAV LLQTPTQAGE EPLNVGSVAA
361 GGRYDGLVGM FDPKGHKVPC VGLSIGVERI FYIVEQRMKT KGEKVRTTET QVFVATPQKN
421 FLQERLKLIA ELWDSGIKAE MLYKNNPKLL TQLHYCESTG IPLVVIIGEQ ELKEGVIKIR
481 SVASREEVAI KRENFVAEIQ KRLSESLocalizationUniProt · AlphaFold · HPA
Whether an antibody against HARS2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 31 nTPM
Expression across tissuesHPA
Tissue
- skeletal muscle: 31 nTPM
- tongue: 27 nTPM
- choroid plexus: 22 nTPM
- heart muscle: 21 nTPM
- rectum: 21 nTPM
- cerebellum: 20 nTPM
Single-cell type
- cardiomyocytes: 19 nCPM
- myonuclei: 19 nCPM
- retinal ganglion cells: 16 nCPM
- fibro-adipogenic progenitors: 15 nCPM
- foveolar cells: 15 nCPM
- retinal bipolar cells: 15 nCPM
Immune cell
- basophil: 38 nTPM
- NK-cell: 30 nTPM
- eosinophil: 29 nTPM
- MAIT T-cell: 21 nTPM
- naive CD8 T-cell: 21 nTPM
- T-reg: 20 nTPM
Brain region
- choroid plexus: 21 nTPM
- white matter: 17 nTPM
- thalamus: 16 nTPM
- pons: 15 nTPM
- hypothalamus: 15 nTPM
- midbrain: 15 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about HARS2.
Disease | AllUniProt
Conditions HARS2 is implicated in, by any mechanism.
- Perrault syndrome 2 (PRLTS2) MIM:614926
Disease | GeneticClinVar
27 pathogenic / likely-pathogenic of 295 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Perrault syndrome 2
- Perrault syndrome
- Sensorineural hearing loss disorder
- Gastric cancer
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.74
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.04
- DepMap mean gene effect
- -0.31
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- histidyl-tRNA aminoacylation
- mitochondrial translation
- translation
- tRNA aminoacylation for protein translation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Anticodon-binding
- Histidine-tRNA ligase/ATP phosphoribosyltransferase regulatory subunit
- Aminoacyl-tRNA synthetase, class II
- Histidine-tRNA ligase
- Histidyl-anticodon-binding
- Anticodon-binding domain superfamily
- Class II Histidinyl-tRNA synthetase (HisRS)-like catalytic core domain
- Class II Aminoacyl-tRNA synthetase/Biotinyl protein ligase (BPL) and lipoyl protein ligase (LPL)
- Anticodon binding domain
- Histidyl-tRNA synthetase
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of HARS2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads HARS2 as an antibody target. Whether an autoantibody or antibody against HARS2 could matter depends on whether native HARS2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
HARS2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label HARS2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...